Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029

NCT03083808 is registered in ClinicalTrials.gov with Greg Durm, MD as lead sponsor.

NCT NCT03083808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03083808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029
Lead sponsor
Greg Durm, MD
Phase
Phase 2
Overall status
Completed
Start date
March 20, 2017
Completion date
March 3, 2022
Enrollment
35 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung cancer